Coloplast reported resilient Q4 2025 results, with an adjusted EBIT beat offsetting a slight revenue miss. Solid chronic care growth, improving margins and strong Kerecis momentum contrast with China headwinds, product recalls and a cautious FY26 outlook during the ongoing CEO transition.
Published on 11/04/2025
at 12:26 pm EST - Modified on 11/04/2025
at 11:55 am EST
Coloplast A/S specializes in the design, manufacturing, and marketing of disposable medical products. Net sales break down by family of products as follows:
- ostomy care products (35.5%): bags and equipment used following intestinal operations;
- hygiene products (32.2%): urine bags, plugs, urinary testing systems and sets, etc.;
- wound care and skincare products (14.1%): wound dressings, bandages, creams and gels;
- interventional urology products (10%);
- voice and respiratory care products (8.2%): voice prostheses for speaking, adhesives, laryngectomy cannulas for breathing, hands-free speaking devices, etc.
Net sales are distributed geographically as follows: Denmark (1.5%), the United States (23.5%), the United Kingdom (14%), France (10.1%), Germany (9.7%) and other (41.2%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
This Alphavalue article, the European leader in independent research, is only available to subscribers .
